author-photo

Cristina Llorca

38

Papers

450

Citations

Citation Trend

Filter By

Papers (38) Sort By

JournalConferenceOthers

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (39)
Transcriptomic characterization of endometrial cancer in order to find new therapeutic targets.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

2018 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (13)
First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Prognostic factors influencing the selection of bevacizumab combined with chemotherapy in patients with HER2-negative metastatic breast cancer in routine clinical practice: Oncosur-Avalox—Observational cross-sectional study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
756PTreatment patterns, clinical characteristics, and outcomes of patients (pts) with metastatic pancreatic cancer (MPC) treated with nab-paclitaxel (nab-P) plus gemcitabine (GEM) in real-life practice: ANICE-Pac trial

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Observational cross-sectional study to evaluate the prognostic factors influencing the selection of bevacizumab combined with chemotherapy in patients with HER2-negative metastatic breast cancer in routine clinical practice. ONCOSUR-AVALOX study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study

2015 Anticancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Association between serum levels of C-reactive protein and response to treatment of chemotherapy-induced anemia in patients with solid tumors: a multicenter, prospective, observational study

2013 Medical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic Factors Influencing the Selection of Bevacizumab Combined With Chemotherapy in Patients With HER2-Negative Metastatic Breast Cancer in Routine Clinical Practice. Oncosur-Avalox: Observational Cross-Sectional Study

2012 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号